- VC 705.08 Cardiac Arrest – VF/VT
- VC 705.09 Chest Pain – Acute Coronary Syndrome
- VC 705.25 Ventricular Tachycardia Sustained – Not in Arrest
- SB 533-09b Cardiac Arrest – VF/VT
- SB 533-11 Chest Pain – Acute Coronary Syndrome
- SB 533-14 Wide Complex Tachycardia – Not in Arrest
- LA County Ref. No. 1210 Cardiac Arrest
- Class III antiarrhythmic agent which inhibits adrenergic stimulation (alpha- and beta-blocking properties), affects sodium, potassium, and calcium channels, prolongs the action potential and refractory period in myocardial tissue; decreases AV conduction and sinus node function
- Management of ventricular fibrillation (VF) or ventricular tachycardia (VT)
- Hypersensitivity to iodine
- Sick sinus syndrome, second- or third-degree atrioventricular block Bradycardia without a functioning artificial pacemaker
- Cardiogenic shock
Adult
Cardiac Arrest due to Ventricular Fibrillation or Pulseless Ventricular Tachycardia
IV, IO: Initial: 300 mg rapid bolus; if ventricular fibrillation or pulseless ventricular tachycardia continues after subsequent defibrillation attempt or reoccurs after initially achieving return of spontaneous circulation, administer a second dose of 150 mg
Ventricular Tachycardia with Pulse
IV, IO: 150 mg over 10 minutes, followed by infusion
Pediatric
Cardiac Arrest due to Ventricular Fibrillation or Pulseless Ventricular Tachycardia
IV, IO: 5 mg/kg (maximum dose: 300 mg/dose) rapid bolus; may repeat twice up to a maximum total dose of 15 mg/kg during acute treatment
Ventricular Tachycardia with Pulse
IV, IO: 5 mg/kg (maximum dose: 300 mg/dose) given over 60 minutes to avoid hypotension
Cardiac arrest: rapid IV push
Patient with pulses: infusion to prevent hypotension
within hours
2 weeks to months
- Pregnancy: In utero exposure may cause fetal harm.
- Monitoring: Monitor ECGs for increasing PR and QT intervals, exacerbation of arrythmias and bradycardia. Respiratory status and blood pressure should be closely monitored
- Cardiovascular
- Hypotension
- Bradycardia
- Atrioventricular block
- Sinoatrial arrest
- Exacerbation of arrhythmias
- Gastrointestinal
- Nausea and vomiting
- Hepatotoxicity
- Pulmonary
- Pulmonary alveolar hemorrhage
- Acute respiratory distress syndrome (ARDS)
- Thyroid effects
- Hyperthyroidism
- Hypothyroidism
